

شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو

بسم الله الرحمن الرحيم





MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكتروني والميكروفيلو



شبكة المعلومات الجامعية التوثيق الالكتروني والميكروفيلم



MONA MAGHRABY



شبكة المعلومات الجامعية التوثيق الإلكترونى والميكروفيلم

جامعة عين شمس التوثيق الإلكتروني والميكروفيلم قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات



يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار



MONA MAGHRABY



Left Ventricular Assist Device Therapy in Heart Failure: A Meta-Analysis

Submitted for Partial Fulfillment of Master's degree in Cardiothoracic Surgery

By

Sandy Yasser Esmaiel
MBBCH (2013)

Under supervision of

Prof. Ahmed Baheig Hosny El Kerdany

Professor of Cardiothoracic Surgery Faculty of Medicine, Ain Shams University

Prof. Hany Abd El Maabood Metwally

Professor of Cardiothoracic Surgery Faculty of Medicine, Ain Shams University

Dr. Ramy Mohamed Reda Khorshid

Lecturer of Cardiothoracic Surgery Faculty of Medicine, Ain Shams University

> Ain Shams University Cairo, Egypt 2021



سورة البقرة الآية: ٣٢



First, thanks to AUAH to whom I relate any success in achieving any work in my life.

I wish to express my deepest thanks, gratitude, and appreciation to **Prof. Dr.**Ahmed Baheig Hosny El Kerdany,
Professor of Cardiothoracic Surgery, for his meticulous supervision, kind guidance, valuable instructions, and generous help.

Special thanks are due to **Prof Dr. Hany Abd El Maabood Metwally,**Professor of Cardiothoracic Surgery, for his sincere efforts, fruitful encouragement.

Special thanks are due to **Dr. Ramy Mohamed Reda Khorshid**, Lecturer of
Cardiothoracic Surgery, for his honest
assistance and active guidance. Many thanks
for the precious time he had given in follow
up of this work.

Sandy

List of Contents

Title	Page No.
List of Tables	i
List of Figures	ii
List of Abbreviations	vii
Introduction	i
Aim of the Work	3
➡ Heart Failure	4
Transplantation & Ventricular Assi	st Devices11
Patients and Methods	20
Results	
Discussion	62
Summary	76
Conclusion	78
Recommendations	79
References	80
Appendix	
Arabic Summary	

List of Tables

Table No.	Title	Page No.
Table (1):	Classification of heart failure ba NYHA and AHA classification sys	
Table (2):	Characteristics of the included stu	ıdies26
Table (3):	Risk of bias assessment	57
Table (4):	Synthesis on the comparative safe different left ventricular assist dev	v 1

List of Figures

Fig. No.	Title Page No.
Figure (1):	Global epidemiology pattern of heart failure5
Figure (2):	Neuroendocrine compensatory mechanisms in HFrEF7
Figure (3):	Adverse events of heart transplantation14
Figure (4):	Illustration of different LVAD types, including HearMate II, HeartMate III, and HVAD (HeartWare)16
Figure (5):	Drawing of the three major continuous flow left ventricular assist devices currently implanted16
Figure (6):	Adverse events of left ventricular assist devices (LVADs)19
Figure (7):	Study flow chart25
Figure (8):	Forest plot of 1-year mortality comparing LVAD to heart transplantation27
Figure (9):	Funnel plot of the studies assessing 1-year mortality in LVAD compared to heart transplantation
Figure (10):	Forest plot of stroke rates comparing LVAD to heart transplantation
Figure (11):	Funnel plot of the studies assessing stroke rates in LVAD compared to heart transplantation28
Figure (12):	Forest plot of infection rates (including sepsis) comparing LVAD to heart transplantation29
Figure (13):	Funnel plot of the studies assessing infection rates in LVAD compared to heart transplantation29
Figure (14):	Forest plot of bleeding rates (including GI bleeding) comparing LVAD to heart transplantation30
Figure (15):	Funnel plot of the studies assessing bleeding rates in LVAD compared to heart transplantation30
Figure (16):	Forest plot of hospital readmission rates comparing LVAD to heart transplantation31

Fig. No.	Title Pag	e No.
Figure (17):	Funnel plot of the studies assessing hosp readmission rates in LVAD compared to h transplantation	eart
Figure (18):	Forest plot of renal failure rates comparing LVA heart transplantation	32
Figure (19):	Funnel plot of the studies assessing renal fair rates in LVAD compared to heart transplantation	
Figure (20):	Forest plot of right ventricular failure r comparing LVAD to heart transplantation	
Figure (21):	Funnel plot of the studies assessing reventricular failure rates in LVAD compared heart transplantation	d to
Figure (22):	Forest plot of 1-year mortality rates compa bridge to transplantation (BTT) to destina therapy with LVAD (DT)	tion
Figure (23):	Funnel plot of the studies assessing the 1-mortality rates in BTT compared to DT	•
Figure (24):	Forest plot of infection rates comparing bridg transplantation (BTT) to destination therapy LVAD (DT)	with
Figure (25):	Funnel plot of the studies assessing the infectates in BTT compared to DT	
Figure (26):	Forest plot of stroke rates comparing bridge transplantation (BTT) to destination therapy v LVAD (DT)	with
Figure (27):	Funnel plot of the studies assessing the strates in BTT compared to DT	
Figure (28):	Forest plot of bleeding rates comparing bridg transplantation (BTT) to destination therapy LVAD (DT)	with
Figure (29):	Funnel plot of the studies assessing the bleed rates in BTT compared to DT	_
Figure (30):	Forest plot of renal failure rates comparing bridg transplantation (BTT) to destination therapy LVAD (DT)	with

Fig. No.	Title	Page No.
Figure (31):	Funnel plot of the studies assessing failure rates in BTT compared to DT	
Figure (32):	Forest plot of right ventricular fail comparing bridge to transplantation destination therapy with LVAD (DT)	(BTT) to
Figure (33):	Funnel plot of the studies assessing ventricular rates in BTT compared to DT	•
Figure (34):	Forest plot of device malfunction rates bridge to transplantation (BTT) to otherapy with LVAD (DT)	destination
Figure (35):	Funnel plot of the studies assessing malfunction rates in BTT compared to D	
Figure (36):	Forest plot of 1-year mortality rates HeartWare to HeartMate II	
Figure (37):	Funnel plot of the studies assessing mortality rates in HeartWare con HeartMate II	npared to
Figure (38):	Forest plot of VAD infection rates HeartWare to HeartMate II	
Figure (39):	Funnel plot of the studies assessing infection rates in HeartWare con HeartMate II	npared to
Figure (40):	Forest plot of non-VAD infection rates HeartWare to HeartMate II	
Figure (41):	Funnel plot of the studies assessing the infection rates in HeartWare com HeartMate II	npared to
Figure (42):	Forest plot of bleeding rates comparing to HeartMate II	
Figure (43):	Funnel plot of the studies assessing the rates in HeartWare compared to HeartM	•
Figure (44):	Forest plot of neurological event rates HeartWare to HeartMate II	

Fig. No.	Title	Page No.
Figure (45):	Funnel plot of the studies assert neurological events rates in HeartWare to HeartMate II	compared
Figure (46):	Forest plot of hospital readmiss comparing HeartWare to HeartMate II	
Figure (47):	Funnel plot of the studies assessing the readmission rates in HeartWare con HeartMate II	npared to
Figure (48):	Forest plot of device malfunction rates HeartWare to HeartMate II	
Figure (49):	Funnel plot of the studies assessing malfunction rates in HeartWare con HeartMate II	npared to
Figure (50):	Forest plot of pump thrombosis rates HeartWare to HeartMate II	
Figure (51):	Funnel plot of the studies assessing thrombosis rates in HeartWare con HeartMate II	npared to
Figure (52):	Forest plot of right ventricular fail comparing HeartWare to HeartMate II	
Figure (53):	Funnel plot of the studies assessing ventricular failure rates in HeartWare of HeartMate II	ompared to
Figure (54):	Forest plot of 1-year mortality rates HeartMate III to HeartMate II	
Figure (55):	Funnel plot of the studies assessing mortality rates in HeartMate III con HeartMate II	mpared to
Figure (56):	Forest plot of stroke rates comparing I III to HeartMate II	
Figure (57):	Funnel plot of the studies assessing rates in HeartMate III compared to Hear	
Figure (58):	Forest plot of VAD infection rates HeartMate III to HeartMate II	1 0

Fig. No.	Title	Page No.
Figure (59):	Funnel plot of the studies assessing infection rates in HeartMate III cor HeartMate II	npared to
Figure (60):	Forest plot of bleeding rates comparing III to HeartMate II	
Figure (61):	Funnel plot of the studies assessing the rates in HeartMate III compared to Heart	
Figure (62):	Forest plot of right ventricular fail comparing HeartMate III to HeartMate	
Figure (63):	Funnel plot of the studies assessing ventricular failure rates in HeartMate III to HeartMate II	compared
Figure (64):	Forest plot of pump thrombosis rates HeartMate III to HeartMate II	
Figure (65):	Funnel plot of the studies assessing thrombosis rates in HeartMate III con HeartMate II	mpared to
Figure (66):	Forest plot of device malfunction rates HeartMate III to HeartMate II	
Figure (67):	Funnel plot of the studies assessing malfunctions rates in HeartMate III co HeartMate II	mpared to
Figure (68):	Risk of bias summary of the included stu	dies58
Figure (69):	Risk of bias graph with each risk of presented as percentages across all include	
Figure (70):	Forest plot comparing overall outcomes of vs HeartMate II demonstrating significant rates of VAD infections, neurological event ventricular failure, while lower rates thrombosis in HeartWare vs HeartMate II	ntly higher s and right of pump
Figure (71):	Forest plot comparing overall outcomes of II vs HeartMate III demonstrating significant rates of stroke, device malfunction at thrombosis in HeartMate III vs HeartMate	antly lower and pump

List of Abbreviations

Abb.	Full term
ACE	Angiotensin converting enzyme inhibitor
AF	Atrial Fibrillation
AHA	American Heart Association
AHF	Acute Heart Failure
BiVAD	Biventricular Assist Device
BTT	Bridge to transplantation
CAV	$Cardiac\ allograft\ vasculopathy$
CF- LVAD	Continuous Flow Left Ventricular Assist Device
CI	Confidence Interval
CV	Cardiovascular
DCD	Donation after circulatory death
dd-cfDNA	Donor-derived cell-free DNA
DT	Destination therapy
ECD	Extended criteria donor
EKB	Egyptian Knowledge Bank
ENDURANCE	The HeartWare® Ventricular Assist System as Destination Therapy of Advanced Heart Failure
EUROMACS	European Registry for Patients with Mechanical Circulatory Support
FDA	Food and Drug Administration
GI	Gastrointestinal
GRADE	Grading of Recommendations, Assessment, Development and Evaluation
HF	Heart failure

List of Abbreviations (Cont...)

Abb.	Full term
HFmrEF	Heart failure with mid-range ejection fraction
HFpEF	Heart failure with preserved ejection fraction
HFrEF	Heart failure with reduced ejection fraction
HMII	HeartMate II
HMIII	HeartMate III
HTx	Heart Transplantation
HVAD	HeartWare Ventricular Assist Device
I 2	Heterogenicity Index
ISHLT	The International Society for Heart and Lung Transplantation
<i>IV</i>	Intravenous
LV	Left Ventricle
LVAD	Left Ventricular Assist Device
LVEF	Left Ventricular Ejection Fraction
MI	Myocardial Infarction
MOF	Multiple Organ Failure
MOMENTUM	Multicenter Study of MagLev Technology in Patients Undergoing Mechanical Circulatory Support Therapy with HeartMate 3
MRA	$Mineralo cortico id\ Receptor\ Antagonist$
mRS	Modified Rankin Scale
NYHA	New York Heart Association
OR	$Odds\ Ratio$